Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Halozyme Therapeutics Inc. buy Benchmark Co.

Start price
€50.28
18:30 / 50%
Target price
€55.00
08.08.25
Performance (%)
-
Price
-
-
Summary
This prediction has just been started. It does not have a price yet.. This prediction currently runs until 08.08.25. The prediction end date can be changed by Benchmark_Co_ at any time.
Performance without dividends (%)
Name 1w
Halozyme Therapeutics Inc. -
iShares Core DAX® -5.630%
iShares Nasdaq 100 -8.559%
iShares Nikkei 225® -9.576%
iShares S&P 500 -6.631%

Comments by Benchmark_Co_ for this prediction

In the thread Halozyme Therapeutics Inc. diskutieren
Prediction Buy
Perf. (%) -
Target price 54.996
Change
Ends at 08.08.25

Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $60.00 price target on the stock.
Ratings data for HALO provided by MarketBeat

Stopped prediction by Benchmark_Co_ for Halozyme Therapeutics Inc.

buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€48.68
25.06.24
€56.00
25.06.25
3.29%
17:58

buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€36.23
16.04.24
€46.98
16.04.25
37.59%
17:58

buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€31.35
19.01.24
€45.94
19.01.25
60.38%
17:58

buy
Halozyme Therapeutics Inc.

Start price
Target price
Perf. (%)
€33.23
20.10.23
€47.17
20.10.24
51.31%
17:58